Brit J Cancer:接受阿那曲唑治疗5年的绝经后妇女骨密度变化

2021-01-25 MedSci原创 MedSci原创 发表于上海

这是第一个报告停止阿那曲唑预防乳腺癌患者中BMD变化的研究。该研究的结果表明,阿那曲唑用于预防乳腺癌对BMD的负面影响部分是可逆的。

阿那曲唑治疗期间与显著加速的骨密度(BMD)丢失有关。近日,肿瘤学领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员纳入了1410名绝经后妇女,她们被纳入BMD亚组研究,根据她们脊柱或股骨颈的基线T评分得分为三个层次。

这项分析的主要目的是调查那些没有接受二膦酸盐治疗的患者,在停止治疗两年后(第5年至第7年),脊柱和髋关节的双能X线吸收测定法(DXA)测定的BMD是否发生变化。

该研究共有528名未接受二膦酸盐治疗的妇女获得了5年和7年的BMD数据。在基线时BMD正常的女性中,研究人员观察到阿那曲唑停药后腰椎BMD增加了1.25% (95%CI为0.73-1.77) (P=0.0004),比安慰剂组增加幅度要大(0.14%(−0.29-0.56))。髋关节方面,服用阿那曲唑组患者的BMD在5-7年间保持不变,而随机分至慰剂组的BMD继续下降(-1.35%(-1.70至-0.98))。

由此可见,这是第一个报告停止阿那曲唑预防乳腺癌患者中BMD变化的研究。该研究的结果表明,阿那曲唑用于预防乳腺癌对BMD的负面影响部分是可逆的。

原始出处:

Ivana Sestak.et al.Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.Brit J Cancer.2021.https://www.nature.com/articles/s41416-020-01228-2

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-08-01 ms1000002016287811

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-02-01 Mr.d

    学习中

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-27 zxxiang
  7. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-26 MaYazhen

    学习中

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-25 ms9000000784262906

    学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-25 ms3000001188646769

    了解

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1004415, encodeId=c08e1004415f2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc115448783, createdName=ms1000002016287811, createdTime=Sun Aug 01 15:57:31 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=922009, encodeId=df6492200950, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200820/a50c79dfbf8443c28d9507e5ed481752/4f3848e242344bd8a14c3db699d30a7b.jpg, createdBy=da5f5248805, createdName=Mr.d, createdTime=Mon Feb 01 19:03:19 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257258, encodeId=3811125e258ad, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1332023, encodeId=fdb5133202323, content=<a href='/topic/show?id=0ab6e8887cc' target=_blank style='color:#2F92EE;'>#绝经后妇女#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78887, encryptionId=0ab6e8887cc, topicName=绝经后妇女)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412272, encodeId=98b914122e2ff, content=<a href='/topic/show?id=e9b69e95040' target=_blank style='color:#2F92EE;'>#阿那曲唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97950, encryptionId=e9b69e95040, topicName=阿那曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=418d2846303, createdName=jiangfeng5068, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631640, encodeId=a03316316404f, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Wed Jan 27 10:43:16 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919942, encodeId=a9de9199422d, content=学习中, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200818/880c1c6388a746ba9d119bfcdc861297/62661b3226e441b08d535541976faa6a.jpg, createdBy=d42d2088603, createdName=MaYazhen, createdTime=Tue Jan 26 09:43:07 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919883, encodeId=065a91988330, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1fa5455810, createdName=ms9000000784262906, createdTime=Mon Jan 25 22:57:44 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919855, encodeId=8e4191985572, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e465455785, createdName=ms3000001188646769, createdTime=Mon Jan 25 21:54:22 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919850, encodeId=260d91985044, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 25 21:11:13 CST 2021, time=2021-01-25, status=1, ipAttribution=)]
    2021-01-25 wxl882001

    了解

    0

相关威廉亚洲官网

CLIN CANCER RES:AKT抑制剂MK-2206联合阿那曲唑治疗Ⅱ/Ⅲ期PIK3CA突变ER阳性和HER-2阴性乳腺癌

ER受体阳性乳腺癌中AKT高度活化且与内分泌耐药有关。在临床前研究中AKT抑制剂MK-2206可以在雌激素剥夺情况下诱导PIK3CA突变ER阳性乳腺癌凋亡。CLIN CANCER RES近期发表了一篇文章,研究阿那曲唑联合MK-2206是否可以诱导PIK3CA突变ER阳性乳腺癌出现病理完全缓解(pCR)。

Lancet oncol:芳香化酶抑制剂治疗乳腺癌的更佳时间,以及三种芳香化酶抑制剂的疗效对比

目前,利用芳香化酶抑制剂辅助治疗乳腺癌的最佳时间尚不确定,现也无临床试验直接对比三种芳香化酶抑制剂阿那曲唑(anastrozole)、依西美坦(exemestane)和来曲唑( letrozole)的效果。近日,Lancet子刊上发表一篇文章,研究人员对芳香化酶抑制剂用作辅助治疗雌激素受体阳性的早期乳腺癌的时间和类型进行评估。研究人员进行多中心的、开放性、随机化临床三期试验(FATA-GIM3),

Lancet:阿那曲唑用于乳腺癌的预防

研究认为,阿那曲唑可降低绝经后乳腺高风险人群的侵袭性雌激素受体阳性乳腺癌和导管原位癌风险

Fertil Steril.:雄激素缺乏生育力低下男性接受阿那曲唑 结局有何改善?

2017年3月,发表在《Fertil Steril》的一项由美国科学家进行的研究考察了阿那曲唑在少精症雄激素缺乏生育力低下男性中的结局。

Fertil Steril:雄激素缺乏生育力低下男性接受阿那曲唑 结局有何改善?

2017年3月,发表在《Fertil Steril》的一项由美国科学家进行的研究考察了阿那曲唑在少精症雄激素缺乏生育力低下男性中的结局。

Int J GynecolCancer:阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

研究背景:有证据表明,一部分复发性卵巢癌患者能够受益于抗雌激素治疗。Paragon试验包括一系列评价阿那曲唑在雌激素受体或孕激素受体阳性的复发性妇科肿瘤患者中治疗效果的研究。本文报道阿那曲唑在雌激素受体或孕激素受体阳性的、铂类耐药的、复发性卵巢上皮癌患者中的治疗效果。研究方法:选取雌激素受体或孕激素受体阳性且铂类耐药的复发性卵巢上皮癌患者入组并应用实体瘤治疗疗效评价标准(Response Eval